Bedrijfsoverzicht
Evolus, Inc. is a performance beauty company that delivers proprietary aesthetic products in the cash-pay market across the United States, Canada, Europe, and Australia. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical formulations rather than broad-market drugs. This operational scale is reflected in a market capitalization of $277.81M and an annual revenue of $297.18M, supported by a workforce of 334 employees. The market cap figure of $277.81M indicates a mid-cap position, suggesting the company has established a foothold in the specialty drug market but remains smaller than large-cap pharmaceutical peers, while the revenue of $297.18M demonstrates a significant operational footprint within the global aesthetic medicine landscape.
Financiële gezondheid
The company reported a revenue of $297.18M over the trailing twelve months, yet the net income stood at -$51,641,000, creating a substantial gap that reveals a heavy cost structure likely driven by research and development or sales and marketing expenses typical for a manufacturer introducing proprietary formulations. EBITDA for the period was -$30,094,000, indicating that while operating cash generation is less negative than net income due to non-cash charges, the entity is not yet generating positive core operating cash flow. Free cash flow amounted to -$26,697,750, which signifies a lack of financial flexibility as the company is currently burning cash rather than accumulating reserves for organic growth or acquisitions. The gross margin stands at 66.3%, which is robust for the industry and suggests high pricing power or efficient production costs relative to the sales price, whereas the operating margin of -0.3% and profit margin of -17.4% highlight significant overhead costs that are eroding the bottom line before interest and taxes. On the balance sheet, the company holds $53.83M in cash against $155.00M in debt, resulting in a negative equity position reflected by a price to book ratio of -12.03, which indicates a highly leveraged financial structure where liabilities significantly outweigh equity. The debt-to-equity ratio is listed as N/A due to the negative equity, precluding a traditional leverage analysis. Liquidity is supported by a current ratio of 1.90, suggesting the company possesses sufficient current assets to cover its short-term obligations without immediate distress. Return on Equity is N/A because there is no positive equity base to generate a return, and the return on assets is -10.3%, revealing that the asset base is currently generating a negative return on the capital employed.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is 17.79, implying that the market prices the stock based on anticipated future profitability rather than current results. The price-to-book ratio of -12.03 indicates that the market values the company at a significant discount relative to its book value, a common valuation characteristic for biotechnology or specialty drug firms with intangible assets and negative equity. The price-to-sales ratio of 0.93 suggests the company trades at roughly one dollar of market value for every dollar of sales, a metric often used when earnings are not yet profitable, while the EV/EBITDA of -12.59 further underscores the negative earnings generation. The stock has traded between a 52-week low of $3.86 and a 52-week high of $12.28, meaning the current market price sits somewhere within this historical range, reflecting the volatility typical of growth-stage healthcare companies. The beta of 1.00 indicates that the stock's price volatility mirrors the broader market, suggesting it does not offer a significant hedge against market downturns nor does it amplify market swings beyond the standard deviation of the index.
Growth & Income
Revenue growth year-over-year is 14.4%, demonstrating a strong top-line expansion trajectory, whereas earnings growth is N/A, indicating that profitability has not yet scaled proportionally to revenue and that the company is still in a reinvestment phase. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which aligns with the strategy of retaining all earnings to fund operations, R&D, and debt reduction rather than distributing cash to shareholders. This reinvestment approach is necessary given the negative free cash flow and the need to build a stronger balance sheet before returning capital to investors. Overall, the growth profile is characterized by expanding revenue streams in a niche aesthetic market, while the income profile remains in a development stage with no current dividends and negative earnings per share.